Short answer
Steris (STE) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1.5B (up 7.3% year over year) with net income of $200M.
Q2 2026 key financials · XBRL
- Revenue
- $1.5B
- +7.3% YoY
- Net income
- $200M
- +12.8% YoY
- Operating margin
- 19.1%
- Gross margin
- 45.8%
Source: XBRL data from the Steris (STE) Q2 2026 10-Q on SEC EDGAR. USD.
Steris Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1,492.7M, up 7.3% YoY from $1,391.1M
- Gross margin 45.8% vs 45.1% YoY; operating income $285.8M vs $246.0M
- Best segment Life Sciences revenue $146.7M, up 8.6%; Healthcare largest at $1,048.3M, up 7.6%
- Operating cash flow $367.1M vs $420.0M; free cash flow $279.6M vs $326.5M
- Debt-to-total capital 20.9% vs 21.3%; dividends $0.63/share; planned restructuring charges $55M–$70M through fiscal 2030
Risk Factors
- No material risk-factor changes disclosed; 10-Q refers to March 31, 2026 Form 10-K
- Capital-allocation risk: New $1,000.0 million repurchase authorization replaced prior $500.0 million program
- Share-repurchase liquidity risk: $100.0 million spent, leaving $900.0 million available at June 30, 2026
- Regulatory-compliance risk: No directors or officers adopted, modified, or terminated Rule 10b5-1 arrangements during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Steris quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.